Skip to main content
SpringerLink
Log in

Pharmakokinetik von Tumortherapeutika bei normaler und eingeschränkter Nierenfunktion

  • Chapter
  • First Online:
Onko-Nephrologie

  • 656 Accesses

Zusammenfassung

Die pharmakokinetischen Prozesse sind Absorption, Distribution, Metabolisierung, und Exkretion (ADME). Absorption ist die Aufnahme eines Arzneimittels vom Applikationsort, Distribution die Verteilung im Körper, Metabolisierung die chemische Modifikation eines Arzneistoffs, bei der dieser in Metaboliten umgewandelt wird (z. B. hepatische Metabolisierung) und Exkretion die Ausscheidung von Arzneistoffen und Metaboliten aus dem Körper (z. B. biliäre Exkretion, renale Exkretion). Elimination ist die Folge von Metabolisierung und Exkretion.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Benet LZ, Hoener BA (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115–121

    Article  CAS  Google Scholar 

  • Czock D, Keller F, Seidling HM (2012) Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs. Br J Clin Pharmacol 74:66–74

    Article  CAS  Google Scholar 

  • Czock D, Rasche FM, Boesler B, Shipkova M, Keller F (2009) Irinotecan in cancer patients with end-stage renal failure. Ann Pharmacother 43:363–369

    Article  CAS  Google Scholar 

  • de Jong FA, van der Bol JM, Mathijssen RH, van Gelder T, Wiemer EA, Sparreboom A, Verweij J (2008) Renal function as a predictor of irinotecan-induced neutropenia. Clin Pharmacol Ther 84:254–262

    Article  Google Scholar 

  • Fujita K, Masuo Y, Okumura H, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Akiyama Y, Kitamura M, Kunishima M, Sasaki Y, Kato Y (2016) Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure. Pharm Res 33:269–282

    Article  CAS  Google Scholar 

  • Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, Dorval E, Piot G, Morel A, Boisdron-Celle M (2008) Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26:2099–2105

    Article  CAS  Google Scholar 

  • Garnier-Viougeat N, Rixe O, Paintaud G, Ternant D, Degenne D, Mouawad R, Deray G, Izzedine H (2007) Pharmacokinetics of bevacizumab in haemodialysis. Nephrol Dial Transplant 22:975

    Article  Google Scholar 

  • Janowitz T, Williams EH, Marshall A, Ainsworth N, Thomas PB, Sammut SJ, Shepherd S, White J, Mark PB, Lynch AG, Jodrell DI, Tavaré S, Earl H (2017) New model for estimating glomerular filtration rate in patients with cancer. J Clin Oncol 35:2798–2805

    Article  CAS  Google Scholar 

  • Jhaveri KD, Flombaum C, Shah M, Latcha S (2012) A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis. J Oncol Pharm Pract 18:140–147

    Article  Google Scholar 

  • Lankheet NAG, Desar IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, van der Graaf WTA, van Erp NP (2017) Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol 83:2195–2204

    Article  CAS  Google Scholar 

  • Moeung S, Chevreau C, Broutin S, Guitton J, Lelièvre B, Ciccolini J, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Paci A, Marsili S, Malard L, Chatelut E, Thomas F (2017) Therapeutic drug monitoring of carboplatin in high-dose protocol (TI-CE) for advanced germ cell tumors: Pharmacokinetic results of a phase II multicenter study. Clin Cancer Res 23:7171–7179

    Article  CAS  Google Scholar 

  • Natarajan H, Kumar L, Bakhshi S, Sharma A, Velpandian T, Kabra M, Gogia A, Ranjan Biswas N, Gupta YK (2018) Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia. Leuk Lymphoma 60:1–8

    Google Scholar 

  • Poole C, Gardiner J, Twelves C, Johnston P, Harper P, Cassidy J, Monkhouse J, Banken L, Weidekamm E, Reigner B (2002) Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 49:225–234

    Article  Google Scholar 

  • Tan ML, Yoshida K, Zhao P, Zhang L, Nolin TD, Piquette-Miller M, Galetin A, Huang SM (2018) Effect of chronic kidney disease on nonrenal elimination pathways: A systematic assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP. Clin Pharmacol Ther 103:854–867

    Article  CAS  Google Scholar 

  • Yoshida K, Sun B, Zhang L, Zhao P, Abernethy DR, Nolin TD, Rostami-Hodjegan A, Zineh I, Huang SM (2016) Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5. Clin Pharmacol Ther 100:75–87

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

    David Czock

  2. Nephrologie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

    Claudia Sommerer

Authors
  1. David Czock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Sommerer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Czock .

Editor information

Editors and Affiliations

  1. Nationales Zentrum für Tumorerkrankungen, Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Dirk Jäger

  2. Nephrologie, Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Martin Zeier

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Czock, D., Sommerer, C. (2020). Pharmakokinetik von Tumortherapeutika bei normaler und eingeschränkter Nierenfunktion. In: Jäger, D., Zeier, M. (eds) Onko-Nephrologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-59911-2_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-59911-2_19

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-59910-5

  • Online ISBN: 978-3-662-59911-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation